SCPS Career Day for Psychiatrists
Saturday, December 8, 2018
10:00 a.m.-3:00 p.m.

Los Angeles County Department of Mental Health
550 S. Vermont Ave.
Los Angeles, CA 90020

Career Day Speakers - 10:00 a.m. - 12 Noon
Managed Care - Galya Rees, M.D.
Private Practice -
Anita Red, M.D.
Academic Psychiatry -
Yvonne Yang, M.D.
Public Psychiatry - Jeremy Mao, M.D.
Group Practice - Victoria Huang, M.D.
Clinical Trials - Haig Goenjian, M.D.
Financial & Investment Strategies - George Fouras, M.D., Zeb Little, M.D.

Employer Exhibits open at 12 Noon - Exhibitors include:
Adelpha Psychiatric Group, Inc.
APA Inc.
California Correctional Healthcare Services
Cedars-Sinai Deptartment of Psychiatry and Behavioral Neurosciences
Community Psychiatry
Family Health Centers of San Diego
Happier Living
Kaiser Permanente
Landmark Health
Las Encinas Hospital
Los Angeles County Department of Mental Health
MHM Services Inc.
Professional Risk Management Services
Riverside University Health System - Behavioral Health
San Fernando Valley Community Mental Health Center
Sites Professionals
Sterling Care Psychiatric Group, Inc.
Telecare Corporation

Box lunch will be served.
(Lunch and Booth Exhibits until 3:00 p.m.)

SCPS Members - Free
Please RSVP to scps2999@earthlink.net by December 4th.

Non-SCPS Members - $15.00

SCPS Presents
Psychopharmacology Update 30

Saturday, January 26, 2019

The Olympic Collection
11301 W. Olympic Blvd.
Los Angeles, CA 90064


8:15 a.m. - Registration, Continental Breakfast, Booth Exhibits
8:55 a.m. - Opening Remarks

9:00 a.m. - Treatment of Obesity
Speaker TBA
Unfortunately, Carlos Grilo has had to cancel his presentation. New speaker will be announced shortly.

10:15 a.m. - Break

10:30 a.m. - Neuromodulation: The Future of Treatment for Neuropsychiatric Illness
Andrew Leuchter, M.D., Professor of Psychiatry and Biobehavioral Sciences; Director, TMS Clinical and Research Service; Director, Neuromodulation Division.
Neuromodulation treatments are an emerging class of technologies that apply magnetic or electrical energy to the brain to treat depression, Obsessive-Compulsive Disorder, chronic pain, and other neuropsychiatric illnesses. Neuromodulation treatments can be used as either an alternative or an addition to medications for the treatment of illness. These cutting edge technologies modify the activity of neural networks, and include non-invasive methods that utilize electromagnets or small electrodes applied to the scalp, and invasive techniques that involve insertion of electrodes into the brain. Non-invasive treatments include repetitive Transcranial Magnetic Stimulation (rTMS), Electroconvulsive Therapy (ECT), transcranial Direct Current Stimulation (tDCS), Trigeminal Nerve Stimulation (TNS), and synchronized Transcranial Magnetic Stimulation (sTMS). Invasive techniques include Deep Brain Stimulation (DBS) and Vagal Nerve Stimulation (VNS). These techniques offer new hope for the the treatment of patients who have received inadequate benefit from medications. This talk will review the effectiveness of neuromodulation treatments that currently are available, as well as major experimental treatments in development.

11:45 a.m. - Lunch Break (on our own)

1:00 p.m. - An Update on Anxiety Disorders
Mark H. Pollack, M.D., The Grainger Professor and Chairman, Department of Psychiatry, Rush University Medical Center.
This talk will review pharmacologic strategies to improve the outcomes for treatment of individuals with anxiety disorders.

2:15 p.m. - The Top Ten Drug Interactions that Limit Efficacy in Psychiatric Treatment
Paul Zarkowski, M.D., Clinical Assistant Professor, Department of Psychiatry and Behavioral Sciences, Harborview Medical Center, University of Washington; Psychiatrist, Sound, Seattle, Washington.
Although there are numerous resources to guide prescribers away from harmful drug interactions and pharmacokinetic interactions, there is less written on interactions that limit efficacy. These are common and can be grouped in three categories including functional drug interactions with opposing functions and side effect profiles, drug interactions with antagonistic mechanisms of action and controversial drug interactions with opposing pharmacology. Each of these categories is represented in the top ten drug interactions that limit efficacy. The relative prevalence of each efficacy limiting interaction will be presented and discussed.


SCPS Member - $200.00
Non-SCPS Member - $225.00
SCPS Resident* - $30.00
Non-SCPS Resident* - $40.00
Above fees effective until 1/15. After 1/15 and at-door registrations additional $25.

*Must be enrolled in a full-time, degree granting program. Must send photocopy of student I.D. with registration form. NO EXCEPTIONS.

To Register with a check, please print - this brochure - (available soon) and mail payment to: SCPS, 2999 Overland Ave. Suite 208, Los Angeles, CA. 90064

Cancellations must be received 48 hours prior to the meeting and will be assessed a $45 administrative processing fee.

- Exhibitors: Please click here for more information -

SCPS would like to thank: Michael Gales, M.D. (Program Chair), David Fogelson, M.D., Jacquelyn Green, M.D., Samuel Miles, M.D., and Heather Silverman, M.D. for planning this event.

5 Hours Category 1 CME will be available for this meeting.

The Southern California Psychiatric Society (SCPS) is accredited by the Institute of Medical Quality/California Medical Association (IMQ/CMA) to provide continuing medical education for physicians. SCPS takes responsibility for the content, quality and scientific integrity of this CME activity.
SCPS designates this educational activity for a maximum of 5 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity. This credit may also be applied to the CMA Certification in Continuing Medical Education.